PT - JOURNAL ARTICLE AU - Wooding, Dominic AU - Buist, Kate AU - Romero-Ramirez, Alessandra AU - Savage, Helen AU - Watkins, Rachel AU - Bengey, Daisy AU - Greenland-Bews, Caitlin AU - Thompson, Caitlin R AU - Kontogianni, Nadia AU - Body, Richard AU - Hayward, Gail AU - Byrne, Rachel L AU - Gould, Susan AU - Group, CONDOR Steering AU - Myerscough, Christopher AU - Atkinson, Barry AU - Shaw, Victoria AU - Greenhalf, Bill AU - Adams, Emily AU - Cubas-Atienzar, Ana AU - Khoo, Saye AU - Fletcher, Tom AU - Edwards, Thomas TI - Optimisation of SARS-CoV-2 culture from clinical samples for clinical trial applications AID - 10.1101/2024.03.25.24304829 DP - 2024 Jan 01 TA - medRxiv PG - 2024.03.25.24304829 4099 - http://medrxiv.org/content/early/2024/03/26/2024.03.25.24304829.short 4100 - http://medrxiv.org/content/early/2024/03/26/2024.03.25.24304829.full AB - Clinical trials of SARS-CoV-2 therapeutics often include virological secondary endpoints to compare viral clearance and viral load reduction between treatment and placebo arms. This is typically achieved using RT-qPCR, which cannot differentiate replicant competent virus from non-viable virus or free RNA, limiting its utility as an endpoint. Culture based methods for SARS-CoV-2 exist; however, these are often insensitive and poorly standardised for use as clinical trial endpoints.We report optimisation of a culture-based approach evaluating three cell lines, three detection methods, and key culture parameters. We show that Vero-ACE2-TMPRSS2 (VAT) cells in combination with RT-qPCR of culture supernatants from the first passage provides the greatest overall detection of Delta viral replication (22/32, 68.8%), being able to identify viable virus in 83.3% (20/24) of clinical samples with initial Ct values <30. Likewise, we demonstrate that RT-qPCR using culture supernatants from the first passage of Vero hSLAM cells provides the highest overall detection of Omicron viral replication (9/31, 29%), detecting live virus in 39.1% (9/23) of clinical samples with initial Ct values < 25. This assessment demonstrates that combining RT-qPCR with virological end point analysis has utility in clinical trials of therapeutics for SARS-CoV-2; however, techniques may require optimising based on dominant circulating strain.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe AGILE platform infrastructure is supported by the Medical Research Council (grant number MR/V028391/1) and the Wellcome Trust (grant number 221590/Z/20/Z).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval was obtained from the National Research Ethics Service (reference 20/WA/0169) and the Health Research Authority (IRAS ID:28422, clinical trial ID: NCT04408170).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript